Revenue has been highly erratic, moving from $77.9M in 2024Q2 to $6.5M in 2026Q1 before the $900.8M spike in 2025Q4, and gross margin swung between -185.8% and 99.9%, suggesting reported profitability is not yet structurally established.
Lakefront Biotherapeutics N.V. (LKFT) annual income statement — 22-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 |
|---|
| Sales/Revenue | 926.95M | 1.11B | 275.65M | 239.72M | 241.25M | 484.85M | 478.05M | 834.9M | 288.84M | 127.09M | 129.52M | 39.56M | 69.37M | 137.7M | 136.27M | 95.89M | 122.41M | 93.09M | 76.98M | 65.94M | 35.15M | 11.24M | 7.78M |
| Revenue Growth % | 223.07% | 303.5% | 14.99% | - | -50.24% | 1.42% | -42.74% | 189.06% | 127.27% | -1.88% | 227.37% | -42.97% | -49.62% | 1.05% | 42.11% | -21.67% | 31.5% | 20.93% | 16.75% | 87.57% | 212.74% | 44.53% | - |
| Cost of Goods Sold | 43.55M | 29.74M | 34.86M | 0 | 31.43M | 1.63M | 523.67M | 420.09M | 322.88M | 218.5M | 139.57M | 129.71M | 111.11M | 41.3M | 48.18M | 124.99M | 116.02M | 85.1M | 27.77M | 30.17M | 19.53M | 4.83M | 1.29M |
| COGS % of Revenue | - | 2.67% | 12.65% | - | 13.03% | 0.34% | 109.54% | 50.32% | 111.79% | 171.93% | 107.77% | 327.87% | 160.17% | 29.99% | 35.36% | 130.35% | 94.78% | 91.41% | 36.07% | 45.75% | 55.57% | 42.96% | 16.56% |
| Gross Profit | 883.41M | 1.08B | 240.79M | 239.72M | 241.25M | 483.22M | -45.61M | 414.81M | -34.04M | -91.42M | -10.06M | -90.15M | -41.74M | 96.4M | 88.09M | -29.1M | 6.39M | 7.99M | 49.21M | 35.77M | 15.62M | 6.41M | 6.49M |
| Gross Margin % | 95.3% | 97.33% | 87.35% | 100% | 100% | 99.66% | -9.54% | 49.68% | -11.79% | -71.93% | -7.76% | -227.87% | -60.17% | 70.01% | 64.64% | -30.35% | 5.22% | 8.59% | 63.93% | 54.25% | 44.43% | 57.04% | 83.44% |
| Gross Profit Growth % | - | 349.57% | 0.44% | - | -50.07% | 1159.36% | -111% | 1318.6% | 62.76% | -808.97% | 88.84% | -115.97% | -143.3% | 9.43% | 402.73% | -555.1% | -19.99% | -83.76% | 37.57% | 129.02% | 143.63% | -1.2% | - |
| Operating Expenses | 272.27M | 581.12M | 429.12M | 327.99M | 372.31M | 648.81M | 133.02M | 46.06M | 333.64M | 216.89M | 141.01M | 129.01M | 105.32M | 106.37M | 90.19M | 3.84M | 4.92M | 6.06M | 61.3M | 50.99M | 26.8M | 12.78M | 10.1M |
| OpEx % of Revenue | - | 52.25% | 155.68% | 136.82% | 154.32% | 133.82% | 27.82% | 5.52% | 115.51% | 170.66% | 108.87% | 326.08% | 151.83% | 77.25% | 66.18% | 4% | 4.02% | 6.51% | 79.63% | 77.33% | 76.25% | 113.7% | 129.83% |
| Selling, General & Admin | 79.81M | 111.96M | 96.88M | 94.25M | 103.31M | 167.22M | 185.22M | 96.96M | 29.64M | 20.56M | 16.95M | 20.31M | 9.08M | 21.76M | 20.4M | 25.39M | 24.07M | 19.01M | 23.4M | 21.9M | 13.94M | 6.16M | 4.65M |
| SG&A % of Revenue | - | 10.07% | 35.15% | 39.32% | 42.82% | 34.49% | 38.75% | 11.61% | 10.26% | 16.18% | 13.08% | 51.33% | 13.09% | 15.8% | 14.97% | 26.48% | 19.66% | 20.42% | 30.4% | 33.21% | 39.64% | 54.79% | 59.84% |
| Research & Development | 189.87M | 459.42M | 335.46M | 241.29M | 269.8M | 491.71M | 523.67M | 420.09M | 322.88M | 218.5M | 139.57M | 129.71M | 111.11M | 99.38M | 80.26M | 0 | 0 | 0 | 38.73M | 30.63M | 15.86M | 6.7M | 5.44M |
| R&D % of Revenue | - | 41.31% | 121.7% | 100.65% | 111.83% | 101.42% | 109.54% | 50.32% | 111.79% | 171.93% | 107.77% | 327.87% | 160.17% | 72.17% | 58.9% | - | - | - | 50.31% | 46.46% | 45.13% | 59.61% | 69.99% |
| Other Operating Expenses | -1000K | 9.74M | -3.21M | -7.56M | -802K | -10.11M | -575.87M | -470.99M | -18.87M | -22.17M | -15.51M | -14.63M | -14.87M | -14.77M | -10.47M | -21.56M | -19.15M | -12.95M | -825K | -1.54M | -2.99M | -78K | 0 |
| Operating Income | 611.14M | 501.39M | -188.34M | -88.26M | -131.06M | -165.6M | -178.63M | 368.75M | -44.81M | -89.8M | -11.49M | -89.44M | -36.62M | -11.02M | -6.61M | -32.94M | 1.03M | 1.66M | -15.21M | -21.84M | -11.81M | -6.65M | -3.61M |
| Operating Margin % | 65.93% | 45.08% | -68.33% | -36.82% | -54.32% | -34.15% | -37.37% | 44.17% | -15.51% | -70.66% | -8.87% | -226.08% | -52.8% | -8% | -4.85% | -34.35% | 0.84% | 1.78% | -19.77% | -33.12% | -33.59% | -59.16% | -46.39% |
| Operating Income Growth % | - | 366.22% | -113.38% | - | 20.86% | 7.3% | -148.44% | 922.97% | 50.1% | -681.5% | 87.15% | -144.22% | -232.34% | -66.72% | 79.93% | -3294.47% | -37.78% | 110.89% | 30.33% | -84.97% | -77.55% | -84.31% | - |
| EBITDA | 493.53M | 557.27M | -142.84M | -44.62M | -65.49M | -144.29M | -170.67M | 374.24M | -39.73M | -85.52M | -7.31M | -86.04M | -31.98M | -2.87M | 2.4M | -20.84M | 12.67M | 8.61M | -7.85M | -13.49M | -7.08M | -5.33M | -2.6M |
| EBITDA Margin % | 53.24% | 50.1% | -51.82% | -18.61% | -27.15% | -29.76% | -35.7% | 44.82% | -13.75% | -67.29% | -5.64% | -217.48% | -46.09% | -2.08% | 1.76% | -21.73% | 10.35% | 9.25% | -10.2% | -20.45% | -20.14% | -47.46% | -33.5% |
| EBITDA Growth % | 245.82% | 490.14% | -220.12% | - | 54.61% | 15.46% | -145.61% | 1042.06% | 53.55% | -1070.02% | 91.51% | -169.09% | -1015.67% | -219.47% | 111.51% | -264.53% | 47.07% | 209.72% | 41.8% | -90.45% | -32.73% | -104.8% | - |
| D&A (Non-Cash Add-back) | 3.04M | 55.88M | 45.5M | 43.64M | 65.57M | 21.3M | 7.96M | 5.5M | 5.08M | 4.29M | 4.18M | 3.4M | 4.65M | 8.15M | 9.01M | 12.1M | 11.63M | 6.96M | 7.37M | 8.35M | 4.73M | 1.31M | 1M |
| EBIT | 490.49M | 303.09M | -2.17M | 7.39M | -61.69M | -122.23M | -178.63M | 368.75M | -30.64M | -114.57M | -11.49M | -119.58M | -35.09M | -15.98M | -5M | -33.59M | 2.15M | 2.4M | -9.25M | -21.72M | -11.44M | -6.28M | -3.41M |
| Net Interest Income | 25.57M | 44.12M | 88.86M | 77.84M | 8.94M | -8.73M | -150.48K | 14.17M | 3.87M | 1.67M | 8.26M | 1.13M | 1.88M | 1.32M | 1.46M | -793K | -443K | 27K | -3.26M | -666K | -687K | -1K | 40K |
| Interest Income | 25.69M | 46.34M | 89.77M | 79.61M | 18.09M | 2.87M | 11.43M | 16.01M | 5.22M | 3.04M | 1.61M | 1.38M | 1.16M | 1.19M | 1.02M | 859K | 1.11M | 738K | 1.86M | 1.08M | 370K | 368K | 202K |
| Interest Expense | 122.27K | 2.22M | 911K | 1.77M | 9.15M | 11.59M | 11.58M | 1.84M | 780K | 936K | 47K | 252.83K | 110K | 157K | 150K | 1.65M | 1.56M | 711K | 5.13M | 1.75M | 1.06M | 369K | 162K |
| Other Income/Expense | 179.88M | -200.52M | 185.25M | 93.89M | 60.21M | 48.57M | -131.14M | -219.89M | 15.6M | -25.7M | 65.74M | -30.18M | 1.42M | 780K | 2.87M | -792K | -443K | 26K | -3.26M | -666K | -687K | -1K | 40K |
| Pretax Income | 791.02M | 300.87M | -3.08M | 5.63M | -70.85M | -123M | -309.77M | 148.85M | -29.21M | -115.51M | 54.25M | -119.63M | -35.2M | -11.19M | -5.15M | -33.73M | 588K | 1.69M | -18.48M | -22.51M | -12.49M | -6.65M | -3.57M |
| Pretax Margin % | 85.34% | 27.05% | -1.12% | 2.35% | -29.37% | -25.37% | -64.8% | 17.83% | -10.11% | -90.89% | 41.88% | -302.37% | -50.75% | -8.13% | -3.78% | -35.17% | 0.48% | 1.81% | -24% | -34.13% | -35.54% | -59.17% | -45.88% |
| Income Tax | 970.38K | -18.62M | -1.8M | 9.61M | 572K | 2.42M | 1.23M | 165K | 50K | 198K | 235K | -1.22M | 2.1M | -3.12M | 569K | -630K | -3.78M | -1.32M | -3.89M | -558K | -1.16M | -110K | 21K |
| Effective Tax Rate % | 0.12% | -6.19% | 58.44% | 170.9% | -0.81% | -1.97% | -0.4% | 0.11% | -0.17% | -0.17% | 0.43% | 1.02% | -5.97% | 27.83% | -11.04% | 1.87% | -643.2% | -78.58% | 21.07% | 2.48% | 9.28% | 1.65% | -0.59% |
| Net Income | 796.09M | 320.88M | 74.08M | 211.7M | -217.99M | -125.42M | -305.44M | 149.84M | -29.26M | -115.7M | 54.01M | -118.41M | 33.21M | -8.08M | -5.72M | -33.1M | 4.37M | 3.01M | -14.58M | -21.95M | -11.34M | -6.54M | -3.59M |
| Net Margin % | 85.88% | 28.85% | 26.88% | 88.31% | -90.36% | -25.87% | -63.89% | 17.95% | -10.13% | -91.04% | 41.7% | -299.29% | 47.88% | -5.87% | -4.2% | -34.52% | 3.57% | 3.23% | -18.95% | -33.29% | -32.25% | -58.19% | -46.15% |
| Net Income Growth % | 282.61% | 333.15% | -65.01% | - | -73.81% | 58.94% | -303.83% | 612.13% | 74.71% | -314.22% | 145.61% | -456.54% | 511.08% | -41.22% | 82.71% | -857.37% | 45.18% | 120.64% | 33.55% | -93.63% | -73.29% | -82.25% | - |
| Net Income (Continuing) | 790.05M | 319.49M | -1.28M | -3.99M | -71.42M | -125.42M | -311M | 148.69M | -29.26M | -115.7M | 54.01M | -118.41M | -37.3M | -16.81M | -5.72M | -33.1M | 4.37M | 3.01M | -14.58M | -21.95M | -11.34M | -6.54M | -3.59M |
| Discontinued Operations | 1.46M | 1.39M | 75.36M | 215.69M | -146.57M | 0 | 5.57M | 1.16M | 0 | 0 | 0 | 0 | 70.51M | 8.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 12.13 | 4.87 | 1.12 | 3.21 | -3.32 | -1.91 | -4.78 | 2.60 | -0.56 | -2.34 | 1.14 | -3.32 | 1.10 | -0.28 | -0.22 | -1.25 | 0.17 | 0.13 | -0.69 | -1.06 | -0.84 | -0.73 | -0.60 |
| EPS Growth % | 279.98% | 334.82% | -65.11% | - | -73.82% | 60.04% | -283.85% | 564.29% | 76.07% | -305.26% | 134.34% | -401.82% | 492.86% | -27.27% | 82.4% | -835.29% | 30.77% | 118.84% | 34.91% | -26.19% | -15.07% | -21.67% | - |
| EPS (Basic) | - | 4.87 | 1.12 | 3.21 | -3.32 | -1.91 | -4.78 | 2.60 | -0.56 | -2.34 | 1.18 | -3.32 | 1.10 | -0.28 | -0.22 | -1.25 | 0.17 | 0.14 | -0.69 | -1.06 | -0.84 | -0.73 | -0.60 |
| Diluted Shares Outstanding | 65.66M | 65.9M | 66.14M | 65.88M | 65.7M | 65.5M | 65.08M | 57.61M | 52.11M | 49.48M | 45.7M | 35.7M | 30.11M | 28.79M | 26.55M | 26.4M | 24.28M | 21.66M | 21.19M | 20.68M | 13.54M | 8.94M | 5.94M |
| Basic Shares Outstanding | 65.66M | 65.9M | 66.14M | 65.88M | 65.7M | 65.5M | 65.08M | 57.61M | 52.11M | 49.45M | 45.7M | 35.67M | 30.08M | 28.79M | 26.55M | 26.4M | 24.28M | 21.66M | 21.19M | 20.68M | 13.54M | 8.94M | 5.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LKFT stock.
For fiscal year 2025, Lakefront Biotherapeutics N.V. (LKFT) reported total revenue of $1.11B. This represents a 14201.8% increase compared to $7.8M in 2004.
Lakefront Biotherapeutics N.V. (LKFT) is profitable, generating $320.9M in net income for the fiscal year ending 2025 with a net profit margin of 28.8%.
Lakefront Biotherapeutics N.V. (LKFT) reported an operating income of $501.4M, resulting in an operating profit margin of 45.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Lakefront Biotherapeutics N.V. (LKFT) generated $1.08B in gross profit for the year, representing a gross profit margin of 97.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Volatile revenue and recurring operating losses
Revenue Erratic Without Clear Durable Trend
Based on reported quarterly figures, LKFT's revenue swung from $77.9M in 2024Q2 to $6.5M in 2026Q1 before a $900.8M spike in 2025Q4, indicating highly irregular top-line behavior that resists trend extrapolation.
The series does not show a stable growth trajectory; instead it alternates between low-teens-millions quarters and isolated large inflows, which suggests revenue may be driven by lumpy one-time items such as licensing or milestone receipts rather than recurring commercial sales. The 2025Q4 figure is roughly an order of magnitude above any other quarter and appears non-recurring based on the reported data, so reported growth rates in that period should not be read as organic momentum. Investors should monitor whether revenue normalizes toward the sub-$15M run-rate seen in 2026 and warrants further investigation into the revenue composition.
Gross Margin Hinges on Lumpy Revenue
Gross margin in LKFT's reported figures ranged from -185.8% in 2026Q2 to 99.9% in 2025Q4, a dispersion that, based on reported figures, reflects cost of revenue that does not scale with the revenue line.
Negative gross margins in several quarters, such as 2024Q2 through 2024Q4 and 2026Q2, indicate that cost of sales has at times exceeded revenue, which may point to manufacturing or fixed-cost absorption issues common to biologics production. The near-100% margin in 2025Q4 appears to reflect a revenue item carrying almost no associated cost, which is not representative of ongoing economics. Peer gross margins of roughly 84% to 98% highlight that LKFT's underlying margin structure has not demonstrated the consistency seen across the comparison group.
Operating Losses Persist Against R&D Burden
As reported in the filings, R&D expense of $25.9M against $7.5M revenue in 2026Q3 produced an operating loss of $40.5M, showing that research spending continues to overwhelm the revenue base.
Operating income has been negative in most quarters outside 2025Q4, and the magnitude of losses does not appear to narrow in proportion to revenue, suggesting limited operating leverage. SG&A and R&D together have frequently exceeded gross profit, which may indicate that the cost base is sized for a commercial scale the company has not yet reached. Until operating expenses are covered by recurring gross profit, the operating line appears structurally dependent on external funding or episodic revenue.
Net Income Dominated by Non-Operating Swings
Based on LKFT's reported figures, net income moved from a $782.1M gain in 2025Q4 to a $202.1M loss in 2025Q3, a divergence from operating results that suggests non-operating items drive reported earnings.
The gap between operating income and net income in several quarters, including the 2025Q4 period where operating income of $758.8M approximates net income, implies that a large share of reported profit is not tied to core operations. Net income in 2026Q1 was positive at $14.5M despite an operating loss of $63.7M, which may reflect non-operating gains, tax effects, or other items not disclosed in the supplied data. These patterns warrant further investigation before reported EPS is treated as a reliable measure of underlying earnings power.
Narrative Rests on Unsustainable Revenue Spike
The strongest challenge to LKFT's reported results is that the $900.8M revenue in 2025Q4 accounts for the bulk of positive earnings, and per the figures, the surrounding quarters show operating losses without that item.
If the 2025Q4 inflow is non-recurring, the trailing profitability picture collapses back toward persistent operating losses seen in 2025Q1 through 2026Q3, and investors may be overestimating the company's earnings base. Short-side analysis would likely focus on the absence of consistent gross profit, recurring R&D intensity relative to revenue, and the sharp EPS reversals between adjacent quarters. Based on the reported data, the burden of proof rests on demonstrating that a repeatable commercial revenue stream exists beyond episodic receipts.